Back to News
Market Impact: 0.2
NovaBridge Acquires YOL104-2 From YOLO Via Visara; To Continue Drug Development For OSSN
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Visara Inc., a subsidiary of NovaBridge Biosciences, announced an asset purchase agreement to acquire worldwide rights to YOLO Immune’s YOL104 program. The article provides no transaction value or other financial terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
NBP0.40
More News
- Futures orbit around SpaceX as Tesla merger talk cheers investors
- Elon Musk Thinks $3.5 Trillion Tesla-SpaceX Mashup Is a Good Idea
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- IBM beats on top and bottom lines as CEO Krishna touts 'Super Intelligence' traction
- Elon Musk says SpaceX and Tesla exploring largest merger in history
- Tesla earnings loom after Musk calls SpaceX merger a 'good idea'